• Govconnect

NHS Long Term Plan 2021 - Partner Profile - Daiichi Sankyo



Who are Daiichi Sankyo?


Daiichi Sankyo UK Ltd is a UK affiliate company with corporate origins in Japan. We create and supply innovative products to help the NHS to deliver better patient care in the fields of cardiovascular disease and oncology.


Our company was founded in 2006 through the merger of Japanese companies Daiichi and Sankyo in Europe. With a rich legacy of scientific expertise dating back more than 100 years, we are the pioneer behind leading pharmaceuticals that have contributed to the improvement of many lives across the world.


Our mission is to contribute to the enrichment of quality of life through the discovery and delivery of innovative medicines that address diverse and unmet medical needs.


We are committed to providing innovation that demonstrates value and supports the NHS in its delivery of sustainable high-quality care, enabling efforts to reduce health inequalities and unwarranted variations and which puts the patient at the heart of the service.


How does Daiichi Sankyo work with the NHS to improve outcomes for patients?


Being a trusted partner of the NHS means more than selling medicines. Our focus is to make a positive impact in how healthcare is delivered for the benefit of patients in the UK. By becoming local NHS experts and proactively listening to our customers and patients, we are able to help support effective change in healthcare delivery that means a win for the NHS, a win for patients and a win for Daiichi Sankyo.


Our medicines portfolio and ‘beyond-the-pill’ service offerings can support the objectives of health policy-makers over the longer-term, at both a system and local level. This is achieved through not only developing and delivering innovation that can meet unmet need in cardiovascular disease, but also through a commitment to partnership and collaborative working.


What has been your greatest achievement to date? And were there any measurable outcomes that accompanied this achievement?


Daiichi Sankyo recently announced a partnership with FibriCheck, neoHealthTech and Capitol Medicare Ltd to improve the detection and diagnosis of Atrial Fibrillation (AF) at home. The collaboration supports the Academic Health Science Network’s Detect, Protect and Perfect initiative and promotes delivery of the NHS’ Long Term Plan by providing digital solutions to patients with an aim to prevent cardiovascular events. This partnership marks a first step in bringing detection and diagnosis of AF into patients’ homes, allowing at-risk patients access to the right treatments at the appropriate time.


The technologies, which consist of the FibriCheck smartphone application and wearable echocardiogram monitoring device, will allow NHS patients with a suspected arrhythmia to be monitored remotely, enabling the detection and diagnosis for otherwise hard-to-reach patients. A number of pilots are currently in progress across a number of NHS organisations testing this solution.


How does Daiichi Sankyo collaborate with partners to help to improve NHS care?


Daiichi Sankyo is committed to working with the NHS to improve patient healthcare. We believe that better patient care can be achieved through collaborative working with the NHS.


Through collaborative working, the NHS and industry organisations pool skills, experience and / or resources for the joint development and implementation of patient centred projects and share a commitment to successful delivery. We work in collaboration with a number of organisations across the UK, including patient advocacy groups, NHS organisations and digital health technology providers. Further information about the scope and content of these projects can be found on our corporate website.


What do you feel are the key points delegates need to digest when considering a partnership with Daiichi Sankyo?


Our company mission is to contribute to the enrichment of quality of life through the discovery and delivery of innovative medicines that address diverse and unmet medical needs.


We are committed to providing innovation that demonstrates value and supports the NHS in its delivery of sustainable high-quality care. This will enable efforts to reduce health inequalities and unwarranted variations, whilst putting the patient at the heart of the service.


If you would like to learn more about Daiichi Sankyo please visit www.daiichi-sankyo.co.uk


Twitter: @daiichisankyoUK

LinkedIn: daiichi-sankyo-uk-ltd


DSC/21/0293 November 2021

5 views0 comments

Recent Posts

See All

NHS Long Term Plan 2021 - Partner Profile - iRhythm

Who are iRhythm? iRhythm Technologies is a digital healthcare company which is redefining the way cardiac arrhythmias are clinically diagnosed with its Zio service. Zio by iRhythm is a NICE-recommende